Mycosis Fungoides
📧 Sign up to get email alerts when something new happens for Mycosis Fungoides.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-10-29Clinical Trial Update: Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies [Phase 2]
Phase II study evaluating Roferon and Accutane in patients with T-cell malignancies completed.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome [Phase 1]
Phase 1 trial investigating gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome (a form of cutaneous T-cell…
-
FDA approval · 2018-09-04FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's original-application generic of Bexarotene for cutaneous T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides [Phase 3]
A Phase 3 trial evaluating doxycycline for early-stage mycosis fungoides in lymphoma patients is underway, with efficacy results not yet spe…
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A [Phase 4]
Phase 4 clinical trial update evaluating photopheresis as an interventional therapy for cutaneous T-cell lymphoma, specifically mycosis fung…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-08-08FDA Approved: POTELIGEO — Original Application (Kyowa Kirin, Inc.)
The FDA approved Poteligeo (mogamulizumab-kpkc) in the original BLA for adults with relapsed or refractory mycosis fungoides or Sézary syndr…
-
CLINICAL_TRIALS trial_result · 2018-07-09Clinical Trial Update: Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides [Phase 2]
Phase 2 trial update evaluating liposomal doxorubicin for patients with recurrent or refractory mycosis fungoides (stages IIB, IVA, or IVB).…
-
CLINICAL_TRIALS trial_result · 2018-07-09Clinical Trial Update: Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides [Phase 3]
Phase 3 study evaluating ultraviolet light therapy using methoxsalen with or without bexarotene for mycosis fungoides; the trial was termina…
-
FDA approval · 2018-05-08FDA Approved: BEXAROTENE — Original Application (ANI Pharmaceuticals, Inc.)
ANI Pharmaceuticals received FDA approval for a generic bexarotene through an Original Application (ANDA). The product is indicated for the …
-
CLINICAL_TRIALS trial_result · 2018-03-16Clinical Trial Update: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) [Phase 3]
Phase 3 trial comparing Brentuximab Vedotin to physician's choice in CD30-positive cutaneous T-cell lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-01-03Clinical Trial Update: Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma [Phase 2]
Phase II trial update for intratumoral IL12 plasmid electroporation in cutaneous T cell lymphomas, including mycosis fungoides; study termin…
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides [Phase 1, Phase 2]
A Phase 1/2 trial comparing low-dose total skin electron beam therapy with vorinostat versus TSEBT alone in mycosis fungoides was terminated…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level [Phase 2]
Phase 2 trial results of brentuximab vedotin (SGN-35) in patients with mycosis fungoides/cutaneous T-cell lymphoma with variable CD30 expres…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) [Phase 2]
A Phase 2 clinical trial evaluating oral vorinostat (SAHA) for advanced cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fun…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
A Phase 2 study evaluating total skin electron beam therapy (12 Gy) for stage IB-IIIA mycosis fungoides has been terminated, with results po…
-
FDA approval · 2016-12-22FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride) topical gel from Helsinn Therapeutics (U.S.), Inc.
-
CLINICAL_TRIALS withdrawal · 2016-12-01Clinical Trial Update: Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. [Phase 1, Phase 2]
A Phase I/II study of intratumoral CPG 7909 (TLR9 agonist) with local radiation for recurrent mycosis fungoides has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-11-29Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 trial of A-dmDT390-bisFv(UCHT1) immunotoxin for cutaneous T-cell lymphoma (CTCL) has completed, with results from the study summariz…
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 study update of the HDAC inhibitor quisinostat in previously treated Cutaneous T-Cell Lymphoma (Stage Ib-IVa) has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides [Phase 2]
Phase 2 clinical trial evaluating the safety and effectiveness of the A-dmDT390-bisFv(UCHT1) fusion protein in patients with mycosis fungoid…
-
CLINICAL_TRIALS research · 2016-08-30Clinical Trial Update: Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides [Phase 2]
A Phase 2 study investigating low-dose total skin electron beam therapy followed by maintenance Valchlor (mechlorethamine gel) for patients …
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
This clinical trial update reports termination of the study NCT01556828, which analyzed cutaneous and hematologic disorders using high-throu…
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Early Diagnosis of Mycosis Fungoides [NA]
The document provides an update on a clinical trial investigating early diagnosis of mycosis fungoides, a form of cutaneous T-cell lymphoma,…
-
FDA approval · 2016-04-08FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for Valchlor (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc.
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL [Phase 2]
A Phase 2 trial investigating a combination of bexarotene and rosiglitazone for cutaneous T-cell lymphoma has been completed, with results p…